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Protein–protein interactions (PPIs) control many cellular pro-
cesses in cancer and tumour growth. Of significant interest is
the role PPIs play in regulating apoptosis. The overexpression
of the antiapoptosis regulating Bcl-2 family of proteins is com-
monly observed in several cancers, leading to resistance to-
wards both radiation and chemotherapies. From this family,
myeloid cell leukemia-1 (Mcl-1) has proven the most difficult
to target, and one of the leading causes of treatment resist-
ance. Exploiting the selective PPI between the apoptosis-regu-
lating protein Noxa and Mcl-1, utilising a fluorescence polariza-
tion assay, we have identified four small molecules with the
ability to modulate Mcl-1. The identified compounds were
computationally modelled and docked against the Mcl-1 bind-
ing interface to obtain structural information about their bind-
ing sites allowing for future analogue design. When examined
for their activity towards pancreatic cell lines that overexpress
Mcl-1 (MiaPaCa-2 and BxPC-3), the identified compounds dem-
onstrated growth inhibition, suggesting effective Mcl-1 modula-
tion.
Protein–protein interactions (PPIs) are involved in many cellular
processes[1] and have therefore emerged as an attractive drug
target in recent years. Specifically they have been shown to
regulate several processes within cancer and tumour growth,[2]
and targeting PPIs is considered a promising strategy towards
next generation anticancer therapeutics.[3] However, PPIs pose
a considerable challenge to the medicinal chemistry communi-
ty due to their large, flat, shallow interfaces, which possess
a high degree of flexibility and thus are deemed problematic
for drug design.[4] Despite this, small molecules have proved
successful at modifying their actions.[5] In particular, modula-
tion of the p53–MDM2 interaction and Bcl-2 family interactions
has been achieved by drug candidates in clinical trials, over-
coming the perception that PPIs are “undruggable”.[6]
The PPIs of the Bcl-2 family play an important role in apop-
tosis as key regulators, a process that is highly conserved and
controlled.[7] The family consists of both pro- and anti-apoptot-
ic proteins, and there is a careful balance within a cell that
controls its fate.[2a] It is believed that upon receipt of cellular
stress, the proapoptotic proteins BAX and BAK are activated by
the BH3-only proteins, where they migrate to the surface of
the mitochondria. Here, they form oligomers and insert them-
selves into the outer mitochondrial membrane forming pores
This process is known as mitochondrial outer membrane per-
meabilisation (MOMP). This in turn leads to the rapid and irre-
versible release of cytochrome c from the mitochondria into
the cytosol, which activates downstream caspases resulting in
apoptosis. High levels of the antiapoptotic proteins (e.g. , Bcl-2,
Bcl-xL and Mcl-1) are often observed in cancer, and they not
only contribute to the development of the tumour but also
confer resistance to current therapies including chemotherapy
and radiation treatment.[2a] In particular, overexpression of
myeloid cell leukemia-1 (Mcl-1) is one of the most common
forms of genetic abnormalities in cancer,[8] with a variety of
human cancers, including pancreatic cancer, exhibiting high
levels of the protein.[9]
The antiapoptotic Bcl-2 family of proteins are well-validated
anticancer targets. The most successful small-molecule inhibi-
tors to date, ABT-737 and its orally available analogue ABT-263
(Navitoclax), inhibit Bcl-2 and Bcl-xL with sub-nanomolar affini-
ty.[10] Although ABT-263 has entered clinical trials, like most
small-molecule Bcl-2 inhibitors, it does not inhibit Mcl-1 and
lacks efficacy in tumours with high levels of Mcl-1 rendering it
ineffective as a single agent.[11] Furthermore, Mcl-1 overexpres-
sion has been linked to resistance observed against paclitaxel
and vincristine,[12] as well as the first-line treatment for pancre-
atic cancer, gemcitabine.[9] Therefore, compounds that specifi-
cally target Mcl-1 have the potential to overcome this resist-
ance. The first selective Mcl-1 inhibitor was identified as recent-
ly as 2010;[13] however, there are currently no compounds un-
dergoing clinical trials that target Mcl-1.
Pancreatic ductal adenocarcinoma has the lowest survival
rates of any cancer.[14] According to Cancer Research UK, less
than 4% of patients diagnosed with the disease will survive for
at least five years, and this drops to less than 3% over a ten-
year period.[15] More worrying though is the fact that these fig-
ures have not changed over the last 40 years despite the re-
search efforts of many groups. Recent studies have shown that
downregulating Mcl-1 enhances the sensitivity of human pan-
creatic cancer cells to gemcitabine and radiation, resulting in
increased levels of apoptosis.[9, 16] Furthermore, knockdown of
Mcl-1 in pancreatic cancer cells treated with ABT-737 triggers
apoptosis, indicating Mcl-1 as an important and significant
therapeutic target in this type of cancer.[17]
The Bcl-2 family has proteins that regulate the activity of
Bcl-2, Bcl-xL and Mcl-1, including Bim, Bid, Puma, Bad, and
Noxa. Of the apoptosis regulator proteins, Noxa displays the
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greatest selectivity towards Mcl-1, binding exclusively to
Mcl-1 and Bfl-1/A1.[18] Interestingly, to the best of our knowl-
edge, only one other group has exploited this selectivity to ex-
plore small-molecule Mcl-1 binding.[19] Herein, we report the
exploration of the Mcl-1 binding pocket and the identification
of novel leads for Mcl-1 inhibition utilising the binding domain
of the selective apoptosis regulating protein Noxa.
To identify potential inhibitors of Mcl-1, we employed a com-
petitive fluorescence polarization (FP) assay similar to the one
we reported for identifying inhibitors of the p53–Mdm2 inter-
action.[20] The assay utilises the 19-residue alpha helix binding
domain of NoxaB (AAQLRRIGDKVNLRQKLLN) tagged on the
N terminus with fluorescein isothiocyanate (FITC) and measures
the competitive binding by the displacement of the tagged
peptide from Mcl-1, resulting in an increase in fluorescence po-
larisation. The NoxaB peptide AAQLRRIGDKVNLRQKLLN was
synthesised on Rink amide resin to generate the amide at the
C terminus. Fluorenylmethyloxycarbonyl (Fmoc)-aminohexanoic
acid was subsequently coupled to the N terminus followed by
coupling with FITC to generate the fluorescently tagged NoxaB
peptide (FITC-NoxaB). A chimeric mouse/human Mcl-1 protein,
previously reported by Colman[21] and used in an FP assay re-
ported by Yu and Wang,[22] was employed by us in the polari-
zation assay. The chimeric Mcl-1 protein has good solubility in
water and maintains the biological function of human Mcl-1,
with the BH3 binding groove consisting entirely of the human
Mcl-1 sequence. An acetylated NoxaB peptide without the ami-
nohexanoic acid or FITC tag was used as a positive control and
exhibited an IC50 value of 0.65 mm and a Ki value of 0.22 mm. To
confirm the reproducibility of our data, a Z-prime test was un-
dertaken producing a result of 0.78 indicating the assay is suit-
able for high-throughput screening.
Following optimisation of the FP assay, we screened the US
National Cancer Institute (NCI) diversity set IV for potential
Mcl-1 inhibitors. The NCI diversity set is a collection of 1600
natural and synthetic compounds with a diverse structural
landscape that have been evaluated as potential anticancer
agents. Compounds were screened initially at a concentration
of 100 mm, and seven compounds were identified as potential
hits (0.44% hit rate). A full dose–response assay revealed that
four of these compounds (Figure 1) displayed an IC50 value of
less than 20 mm in subsequent dose–response assays (Table 1).
The structure of purpurogallin (1) first appears in the litera-
ture in 1882 and is obtained by the oxidation of pyrogallol.[23]
The potential of purpurogallin as a Bcl-2 family binder has
been recognised since 2003,[24] and in 2011, it was part of
a patent that covers small molecules that modulate Mcl-1.[25]
Compound 1 displayed sub-micromolar binding affinity (Ki=
0.80 mm) towards Mcl-1. Our findings support those already re-
ported in the literature and demonstrate the ability of purpur-
ogallin to bind competitively to Mcl-1. The structure of purpur-
ogallin derivative 2 has, to the best of our knowledge, only ap-
peared in the literature twice previously,[26] and here, we have
identified it as a Mcl-1 inhibitor with micromolar affinity (Ki=
6.99 mm). The decreased binding affinity, when compared with
compound 1, suggests that the triphenol moiety is of impor-
tance for binding.
Redoxal (3) was first reported in 1960 as a redox indicator in
alkaline media.[27] It is part of a patent from Cadone and co-
workers that details biphenazine compounds for treating hem-
atopoietic cancers.[28] Compound 3 possessed a binding affinity
in the low micromolar region (Ki=2.95 mm). This could suggest
that the activity observed in hematopoietic cancers by Car-
done could be a result of Mcl-1 modulation, as it has been
widely reported that hematopoietic cancers cells survive for ex-
tended periods due to Bcl-2 family overexpression.[29] Com-
pound 4 was first prepared by Cain and Atwell in 1972 as a po-
tential antitumour agent but was shown to be inactive in the
lymphocytic leukaemia cell line L1210.[30] It has been identified
as a modulator of protein–RNA interactions, specifically the
Gag polyprotein and the viral RNA packaging signal.[31] Here,
we have identified 4 as a novel Mcl-1 binder with low micro-
molar affinity (Ki=1.09 mm). Of the identified compounds, only
compound 1 approached the potency of the untagged NoxaB
control (Ki=0.22 mm), but all compounds demonstrated suffi-
cient activity to be worthy of consideration for further elabora-
tion.
In order to rationalise the binding activity of 1–4 and to fa-
cilitate the structure-based design of analogues, computational
Figure 1. Structures of US National Cancer Institute (NCI) diversity set IV Mcl-
1/mNoxa binding inhibitors 1–4.
Table 1. Activity of compounds 1–4 against Bcl-2 family proteins includ-
ing binding inhibition (IC50) of FITC-mNoxa to Mcl-1, binding affinity con-
stant (Ki), and cell growth inhibition (IC50) of pancreatic cancer cells lines
MiaPaCa-2 and BxPC-3.
Compd Mcl-1[a] MiaPaCa-2 BxPC-3
FP IC50 [mm] FP Ki [mm] IC50 [mm]
[b] IC50 [mm]
[b]
1 1.570.97 0.800.30 17.669.34 >100
2 13.707.35 6.992.40 >100 >100
3 5.780.97 2.950.49 >100 >100
4 2.142.94 1.091.50 88.827.35 15.1110.95
Data represent the meanSD of n=3 independent experiments per-
formed in [a] duplicate or [b] triplicate.
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docking experiments were performed. Computations were
based on the published structure of mouse Mcl-1 bound to
a modified Noxa BH3 peptide (PDB ID: 2NLA).[21] The modified
Noxa and Mcl-1 make key interactions at the Mcl-1 amino
acids Met212, Lys215, Asn223, Asp256 and Arg263 (Fig-
ure 2a).[21] Compound 1 was predicted to bind in a groove cre-
ated by the BH1 and BH3 domains, displaying electrostatic in-
teractions with Arg222 and Val321 (Figure 2b). It sits in a hy-
Figure 2. Computational docking of mNoxa and compounds 1–4 to Mcl-1 (PDB ID: 2NLA[21]). a) Reproduction of the 2NLA crystal structure displaying mNoxa
binding to Mcl-1 in the largely hydrophobic BH3 domain binding groove create by the BH1, BH2 and BH3 domains of Mcl-1, and docking results showing
b) 1 in a largely hydrophobic pocket, c) 2 in a hydrophobic pocket, d) 3 in a similar groove to mNoxa, and e) 4 in a similar groove to mNoxa. Left : ribbon rep-
resentation of Mcl-1 (BH1 (blue), BH2 (green) and BH3 (red) domains) displaying residue interactions of interest (ligand: yellow; atom colours: H=white,
N=blue, O= red) ; Right: the columbic surface representation showing electron rich areas (blue), electron poor areas (red), and hydrophobic areas (white).
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drophobic pocket that is also occupied by the mNoxa peptide.
Compound 2 appears to bind in a similar pocket to 1, shifted
slightly to form electrostatic interactions with Asn223 (compa-
rable to mNoxa) and His224 (Figure 2c). The docking of com-
pound 3 indicated that it might act as a BH3 mimetic, binding
in the mNoxa binding groove created by the BH1, BH2 and
BH3 domains. Electrostatic interactions with His224 and
Asn260 were observed. The ligand is predicted to bind across
the hydrophobic groove, and aromatic stacking interactions
are potentially observed between 3 and Phe319 (Figure 2d).
Similarly, the results of the docking of 4 suggest that it too
may be a BH3 mimetic, binding in a similar manner to com-
pound 3. Docking suggested electrostatic interactions to
Arg222 and the backbone of Gly219 (Figure 2e).
The diverse range of binding interactions predicted by mo-
lecular docking suggests that improvements could be made to
all compounds. A combination of the binders could be ex-
plored, a technique that has been shown to be highly success-
ful at targeting protein–protein interactions.[11,32] Initial consid-
erations would explore the incorporation of the triphenol
moiety of 1, which appears to play an important role in bind-
ing, into compound 4. Additionally, the alteration of aromatic
groups in 4, utilising palladium cross coupling chemistry
during synthesis, could be exploited to increase interactions
with Phe319, an interaction observed in the binding of 1 and
3. The studies also suggest that potential ligands could per-
form well as selective Mcl-1 binders even if they do not mimic
the BH3 domain, and that hydrophobic binding may prove to
be more effective than electrostatic interactions.
Finally, we examined compounds 1–4 for their ability to in-
hibit the growth and induce cell death in pancreatic cell lines
MiaPaCa-2 and BxPC-3. Both cell lines show an increased ex-
pression in Mcl-1 and Bcl-xL, but only MiaPaCa-2 shows an in-
crease in Bcl-2.[33] A summary of the cell growth inhibition is
presented in Table 1. Compounds 2 and 3 displayed no signifi-
cant activity towards either of the cell lines, with IC50 values
greater than 100 mm. Compound 1 inhibited the growth of Mi-
aPaCa-2 with an IC50 value of 17.6 mm, but displayed inhibition
greater than 100 mm towards BxPC-3. Compound 4 demon-
strated inhibition in both MiaPaCa-2 and BxPC-3, with IC50
values of 88.8 mm and 15.1 mm, respectively. These results
could indicate that 1 is capable of modulating Bcl-2 in pancre-
atic cancer, but is ineffective towards Mcl-1. Compound 4
shows micromolar inhibition in both cell lines, perhaps demon-
strating an ability to effectively modulate Bcl-2 family interac-
tions. In fact, Takahashi and co-workers have recently reported
that Bcl-xL and Mcl-1 might co-operatively play a role in the
apoptotic cell death of pancreatic cancer and that targeting
both proteins may be a viable therapeutic strategy.[33]
In summary, we have demonstrated that the selective
Mcl-1 ligand Noxa can be exploited to identify regulators of
the antiapoptotic protein Mcl-1. The modified Noxa peptide
was utilised in a fluorescence polarization assay to screen 1600
compounds, identifying four hits with binding affinities of less
than 10 mm. These compounds were used to explore the bind-
ing pocket of Mcl-1 computationally, allowing for the binding
of mNoxa to be compared with the identified hits (compounds
1–4), identifying potential synthetic enhancements for the
novel binders 2 and 4. The viability of cells treated with com-
pounds 1–4 was examined, demonstrating the ability of 1 and
4 to inhibit the growth of pancreatic cell lines that overexpress
Mcl-1 (MiaPaCa-2 and BxPC-3). Examination of target selectivity,
structure–activity relationship examination, and mode of cell
growth inhibition of compounds 1–4 will be reported in due
course.
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Identification of Small-Molecule
Inhibitors of the Antiapoptotic Protein
Myeloid Cell Leukaemia-1 (Mcl-1)
Breaking up the party: Overexpression
of the antiapoptosis Bcl-2 protein family
members is commonly observed in can-
cers, with myeloid cell leukemia-1 (Mcl-
1) often being responsible for resistance
to radio and chemotherapy. Exploiting
the Mcl-1 selective apoptosis regulating
protein Noxa, novel small molecules ca-
pable of modulating Mcl-1 are identified
and evaluated.
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